Giovanni Caforio
Known title: DirectorCIK: 0001533201
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Transaction History
| SYK | ▲ Buy | Grant | 762 | $0 | 5/6/2026 | View on chart |
| SYK | ▲ Buy | Grant | 560 | $0 | 5/8/2025 | View on chart |
| SYK | ▲ Buy | Grant | 653 | $0 | 5/9/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,409 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 3,687 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 10,088 | $543K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,817 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 10,084 | $542K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 142,904 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 49,745 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 47,651 | $2.6M | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 4,104 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Gift | 440 | $0 | 10/10/2023 | View on chart |
| SYK | ▲ Buy | Grant | 705 | $0 | 5/10/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 841 | $0 | 5/4/2023 | View on chart |
| BMY | ▼ Sell | Other | 4,328 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 14,184 | $932K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,817 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 3,908 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 14,179 | $932K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 22,214 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 718 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 11,728 | $771K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 140,445 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 17,148 | $0 | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,407 | $0 | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 24,793 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 9,042 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 17,304 | $1.1M | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 80,594 | $5.3M | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Open Market | 240,000 | $17.9M | 2/6/2023 | View on chart |
| BMY | ▼ Sell | Open Market | 25,000 | $1.7M | 9/20/2022 | View on chart |
| BMY | ▼ Sell | Open Market | 50,000 | $3.6M | 9/15/2022 | View on chart |
| BMY | ▼ Sell | Open Market | 30,000 | $2.2M | 6/13/2022 | View on chart |
| SYK | ▲ Buy | Option Exercise | 693 | $0 | 5/4/2022 | View on chart |
| BMY | ▼ Sell | Gift | 420 | $0 | 3/22/2022 | View on chart |
| BMY | ▼ Sell | Open Market | 25,000 | $1.8M | 3/21/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 105,761 | $7.2M | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 148,758 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 58,893 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 266 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 9,674 | $662K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 24,793 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 7,535 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 16,466 | $1.1M | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 13,497 | $923K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,817 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 2,672 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 13,492 | $923K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 18,726 | $0 | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 23,407 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 3,092 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Open Market | 30,000 | $2.0M | 2/24/2022 | View on chart |
| BMY | ▼ Sell | Open Market | 25,000 | $1.5M | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.